Source: davit kirakosyan
H.C. Wainwright Retains Neutral Rating for Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Co. (NYSE: BHVN) has maintained a Neutral rating and an $11 price target by H.C. Wainwright, following the release of underwhelming clinical results for its drug, BHV-7000, intended for the treatment of major depressive disorder (MDD). This development reaffirms the cautious perspective held by certain analysts and investors towards Biohaven’s portfolio.
Underwhelming Clinical Results for BHV-7000
Biohaven’s BHV-7000 failed to meet the main goal in its recent clinical trial, which was to demonstrate an improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores over a period of six weeks compared to a placebo. The drug also fell short of reaching secondary endpoints, including the Clinical Global Impressions – Severity scale (CGI-S) and the Snaith-Hamilton Pleasure Scale (SHAPS).
These results come as no surprise to H.C. Wainwright, as the firm noted that investor attention had largely been on the upcoming focal onset seizure readout. Prior to the trial outcome, some investors had hoped that positive MDD data could provide a catalyst for Biohaven’s stock ahead of the FOS results. However, the disappointing results have only served to reinforce a cautious stance.
Exploratory Analysis and Future Direction
Despite the setback, Biohaven plans to conduct additional subgroup analyses. However, H.C. Wainwright has emphasized that these analyses will be exploratory in nature, with no further trials planned for the program. This suggests a change of strategy for Biohaven, potentially redirecting its focus towards other areas of development.
In a bid to maximize their portfolio, Biohaven intends to pivot its focus to priority areas in 2026, which include immunology, obesity, and epilepsy. The decision to shift focus could be a strategic move to diversify the company’s portfolio and explore more promising areas of medical research and development.
Neutral Rating Reaffirmed
Despite the disappointing performance of BHV-7000, H.C. Wainwright has decided to retain its Neutral rating for Biohaven. The analyst added that the BHV-7000 results do not materially affect expectations for Xenon Pharmaceuticals’ Phase 3 MDD program, azetukalner. This suggests that the impact of the BHV-7000 trial results on Biohaven’s overall market standing is minimal and that the company’s potential in other areas of research is not to be underestimated.
Conclusion
The failure of BHV-7000 in its MDD trial represents a setback for Biohaven, but the company’s plans to redirect its focus to other areas of research suggests a resilient strategy. If successful, this could open up new opportunities for the company and its investors. Despite the disappointing results, the reaffirmation of a Neutral rating from a respected firm like H.C. Wainwright indicates that Biohaven still holds potential value in the biotech market. The company’s upcoming focal onset seizure readout is anticipated to garner significant investor attention, and may yet offer a positive catalyst for Biohaven’s market performance.